Android app on Google Play

Sarepta Therapeutic (SRPT) Could Be Worth $83-$139/Sh - Analyst

October 3, 2012 7:58 AM EDT Send to a Friend
Get Alerts SRPT Hot Sheet
Price: $21.56 -0.74%

Rating Summary:
    11 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 9 | New: 11
Trade SRPT Now!
Join SI Premium – FREE
Shares of Sarepta Therapeutic (NASDAQ: SRPT) are surging 132 percent in pre-open trading Wednesday after the company announced that Eteplirsen met it primary endpoint in Duchenne muscular dystrophy (DMD) patients. However, according to one analyst, this may just be the start.

Lazard Capital analyst William Turner said Eteplirsen maximum U.S. rev. opportunity is $750 million and applying 3x-5x market cap/revenue multiple leads to fair value of $83-$139/share.

Despite the positive comments Turner is keeping his Buy rating and price target of $25.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $14.99 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Hot Comments, Momentum Movers, Trader Talk

Related Entities

Lazard

Add Your Comment